Valuation: Genmab

Market Cap 113B 17.46B 15.16B 14.14B 12.99B 24.56B 1,661B 24.83B 167B 65.15B 830B 65.57B 64.14B 2,751B P/E 2026 *
24.1x
P/E 2027 * 16.7x
Enterprise Value 133B 20.45B 17.76B 16.56B 15.21B 28.77B 1,945B 29.08B 195B 76.31B 972B 76.8B 75.12B 3,222B EV / Sales 2026 *
4.7x
EV / Sales 2027 * 3.77x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+54.31%+4.14% - - 17.44B
+10.00%+13.39%+51.99%+83.45% 56.7B
+0.80%-5.70%+23.89%+62.65% 51.97B
-1.01%+0.51%-15.55%-12.73% 23.33B
+0.25%-5.10%-11.17%+349.39% 21.34B
+4.29%+1.67%+201.24%+344.48% 14.77B
+1.80%-0.46%+52.81%+177.50% 13.84B
+3.12%+3.58%+439.66%+180.74% 12.12B
+4.87%-5.44%+63.24%+161.98% 11.14B
+3.00%-0.98%+115.06%+137.03% 10.38B
Average +2.67%-0.84%+102.35%+164.94% 23.95B
Weighted average by Cap. +3.41%+0.47%+67.34%+130.38%

Financials

2026 *2027 *
Net sales 28.25B 4.35B 3.78B 3.52B 3.24B 6.12B 414B 6.19B 41.54B 16.24B 207B 16.34B 15.99B 686B 33.18B 5.11B 4.44B 4.14B 3.8B 7.19B 486B 7.27B 48.79B 19.07B 243B 19.2B 18.78B 805B
Net income 4.82B 742M 644M 601M 552M 1.04B 70.57B 1.05B 7.08B 2.77B 35.28B 2.79B 2.72B 117B 7.05B 1.09B 944M 880M 808M 1.53B 103B 1.55B 10.37B 4.06B 51.68B 4.08B 3.99B 171B
Net Debt 19.4B 2.99B 2.6B 2.42B 2.22B 4.2B 284B 4.25B 28.53B 11.15B 142B 11.23B 10.98B 471B 11.82B 1.82B 1.58B 1.47B 1.35B 2.56B 173B 2.59B 17.38B 6.79B 86.59B 6.84B 6.69B 287B
Logo Genmab
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A